Chasing a Potential $10.75 Billion Psychedelics Market

Psychedelics could change the way we address mental health issues all over the world, creating multi-billion-dollar opportunities along the way.

All as such drugs prove to be a major game changer for millions of people all over the world.  Countless studies are already proving such treatments can treat a host of mental issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders.

Plus, with plenty of clinical trials supporting psychedelic treatments, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines. That’s all big news for companies, such as NeonMind Biosciences (CSE:NEON)(OTC:NMDBF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), KetamineOne (NEO:MEDI)(OTC:KONEF), Mind Medicine Inc. (NEO:MMED)(NASDAQ:MNMD), and Compass Pathways (NASDAQ:CMPS).

A study from JAMA Psychiatry just found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.  Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression. Even ketamine has been found useful in the treatment of depression.

In addition, according to Fortune, “Despite being an industry in its early stages, the potential for psychedelic health care is growing, with the market projected to reach $10.75 billion by 2027.”